Details
Stereochemistry | ACHIRAL |
Molecular Formula | C14H22BrN3O2.ClH |
Molecular Weight | 380.708 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCN(CC)CCNC(=O)C1=CC(Br)=C(N)C=C1OC
InChI
InChIKey=SGQFXUUDHWNAIN-UHFFFAOYSA-N
InChI=1S/C14H22BrN3O2.ClH/c1-4-18(5-2)7-6-17-14(19)10-8-11(15)12(16)9-13(10)20-3;/h8-9H,4-7,16H2,1-3H3,(H,17,19);1H
Originator
Sources: https://www.google.com/patents/US3177252
Curator's Comment: reference retrieved from www.drugfuture.com/chemdata/bromopride.html
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL339 |
|||
Target ID: GO:0004104 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7823770 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Bromopan Approved UsePrincipais: distúrbios digestivos psicossomáticos ad senectude e da estafa mental. Discinesias gastroduodenais e biliares. Colopatias espasmódicas. Enxaquecas e mal-estar de origem celíaca. Náuseas. Vômitos. Anorexia.
Particulares: exames radiológicos do tubo digestivo. Preparação de explorações endoscópicas. Vômitos anestésicos. Soluços. Meteorismo abdominal pós-operatório. Manifestações digestivas após a aplicação de radioterapia. |
Sample Use Guides
In Vivo Use Guide
Sources: http://www.medicinanet.com.br/bula/1015/bromopan.htm
Capsules: 40-60 mg/day
Oral solution: 40-60 mg/day (adults), 0.5-1 mg/kg (children)
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7823770
Bromopride effects on cholinesterase activity in plasma, striatum, duodenum and ileum of adult male rats were measured for drug concentrations ranging from 0.006 to 3.134 microM. Bromopride can inhibit cholinesterase activity in all tissues studied,
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000089001
Created by
admin on Fri Dec 15 17:56:16 GMT 2023 , Edited by admin on Fri Dec 15 17:56:16 GMT 2023
|
PRIMARY | |||
|
m2713
Created by
admin on Fri Dec 15 17:56:16 GMT 2023 , Edited by admin on Fri Dec 15 17:56:16 GMT 2023
|
PRIMARY | Merck Index | ||
|
52423-56-0
Created by
admin on Fri Dec 15 17:56:16 GMT 2023 , Edited by admin on Fri Dec 15 17:56:16 GMT 2023
|
PRIMARY | |||
|
257-906-6
Created by
admin on Fri Dec 15 17:56:16 GMT 2023 , Edited by admin on Fri Dec 15 17:56:16 GMT 2023
|
PRIMARY | |||
|
3016754
Created by
admin on Fri Dec 15 17:56:16 GMT 2023 , Edited by admin on Fri Dec 15 17:56:16 GMT 2023
|
PRIMARY | |||
|
SUB23559
Created by
admin on Fri Dec 15 17:56:16 GMT 2023 , Edited by admin on Fri Dec 15 17:56:16 GMT 2023
|
PRIMARY | |||
|
C013855
Created by
admin on Fri Dec 15 17:56:16 GMT 2023 , Edited by admin on Fri Dec 15 17:56:16 GMT 2023
|
PRIMARY | |||
|
B7C7WX94Z6
Created by
admin on Fri Dec 15 17:56:16 GMT 2023 , Edited by admin on Fri Dec 15 17:56:16 GMT 2023
|
PRIMARY | |||
|
DTXSID50966849
Created by
admin on Fri Dec 15 17:56:16 GMT 2023 , Edited by admin on Fri Dec 15 17:56:16 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD